Secondary Logo

Editorial

New Frontiers in Skin Cancer

del Marmol, Véroniquea; Stratigos, Alexander J.b

Current Opinion in Oncology: March 2019 - Volume 31 - Issue 2 - p 53
doi: 10.1097/CCO.0000000000000509
MELANOMA AND OTHER SKIN NEOPLASMS: Edited by Véronique del Marmol
Free

aDermatology, Hopital Erasme, Université Libre de Bruxelles, Belgium

bMelanoma and Skin Cancer Centre, Department of Dermatology-Venereology, National and Kapodistrian University of Athens, Andeas Sygros Hospital, Athens, Greece

Correspondence to Prof Véronique del Marmol, Dermatology department, Hopital Erasme, 808 route de Lennik, 1070, Brussels, Belgium. E-mail: veronique.del.marmol@erasme.ulb.ac.be

Skin cancer is the most frequent human cancer, and because of more ultraviolet radiation (UVR) exposure and aging of the population, its incidence is still rising. Despite primary prevention campaigns, intense and excessive sun exposure of the population, often with lack or underuse of sun protective measures persist. Indoor tanning beds are a recent additional risk factor of melanoma and, to a lesser extent, of nonmelanoma skin cancer. In this volume, one review is dedicated to the concern of sunbeds and the associated risk of skin cancer, particularly, melanoma.

The 2018 Nobel Prize in medicine was awarded to scientists who discovered the mechanism of negative immune regulation and introduced checkpoint inhibition as a novel cancer therapy. Skin cancer is also beneficiating from this new therapeutic approach of immunotherapy. Indeed, in the last 10 years, the outcome of patients with metastatic melanoma has been drastically improved with targeted therapy [BRAF-inh and MEK-inh (BRAF-inh: vemurafenib, dabrafenib, encorafenib) and MEK-inh (trametinib, cobimetinib, binimetinib)] [in addition to immune checkpoint inhibitors, such as anti CTLA4 inhibitors (ipilimumab) and anti-PD1 inhibitors (nivolumab and pembrolizumab)]. Concerning skin carcinoma, recent breakthrough advances have been also made with anti PDL1/PD1 therapy, first with avelumab (anti-PDL1 inhibitor), which has been approved as first-line therapy for Merkel cell carcinoma. Another new PD1- inhibitor, cemiplimab (anti-PD1) has been approved for advanced cutaneous squamous cell carcinoma whereas its use is explored in advanced BCC refractory to hedgehog inhibitors. Because of these recent developments, the therapeutic approaches in Merkel cell carcinoma and advanced cutaneous squamous cell carcinoma are also reviewed in this volume.

A large population is immunosuppressed because of organ transplantation and/or use of immunosuppressive agents for chronic inflammatory conditions. These patients may present with numerous and aggressive skin squamous cell carcinoma posing significant challenges in their daily management. Dr Aspeslagh and collaborators reviewed the possible approach and limits of immunotherapy for these patients.

In this review volume, we aim to bring to you the latest advances in the epidemiology, diagnosis and treatment of skin cancer through a number of dedicated review articles by experts in the field, whom we sincerely thank. Realizing that this effort is just a ‘capture of moment’ in the rapidly evolving field of skin cancer management, we hope that it will be useful and informative for our readers.

Back to Top | Article Outline

Acknowledgements

None.

Back to Top | Article Outline

Financial support and sponsorship

None.

Back to Top | Article Outline

Conflicts of interest

There are no conflicts of interest.

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.